# Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant

> **NCT02115126** · PHASE2 · WITHDRAWN · sponsor: **David Rizzieri, MD**

## Conditions studied

- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** LMP2A-loaded conventional DC vaccine
- **BIOLOGICAL:** DUK-CPG-001

## Key facts

- **NCT ID:** NCT02115126
- **Lead sponsor:** David Rizzieri, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-12
- **Primary completion:** 2020-01
- **Final completion:** 2025-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115126, "Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02115126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*